Csi 103
Alternative Names: Csi-103Latest Information Update: 03 Sep 2024
At a glance
- Originator Curigin
- Class Antihyperlipidaemics; Hepatoprotectants; Small interfering RNA; Urologics
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Hyperlipidaemia
- Discontinued Liver cirrhosis; Primary hyperoxaluria type 1
Most Recent Events
- 03 Sep 2024 Discontinued for Liver cirrhosis in South Korea (Parenteral) (Curigen pipeline, September 2024)
- 03 Sep 2024 Discontinued for Primary hyperoxaluria type 1 in South Korea (Parenteral) (Curigen pipeline, September 2024)
- 03 Sep 2024 Early research in Hyperlipidaemia in South Korea (Parenteral), prior to September 2024 (Curigen pipeline, September 2024)